Ironwood Pharmaceuticals, Inc. IRWD announced that it has initiated the rolling new drug application (“NDA”) submission for ...

However, as US-China trade relations continue to deteriorate ... including Novartis and Beigene ($2.2 billion), AbbVie and I-Mab ($1.9 billion), and Seagen and RemeGen ($2.4 billion).

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Investors who were hoping for huge dividend increases may want to adjust their expectations. Today, AbbVie's dividend payout ratio is 61% of 2024 earnings. That leaves plenty of room for future ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

AbbVie Inc (Symbol: ABBV ... and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual ...

AbbVie (NYSE:ABBV) will report Q4 2024 results ... being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those ...

Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...